Navigation Links
Syngenta Secures EU Approval For Next Generation Fungicide
Date:11/13/2012

BASEL, Switzerland, Nov. 13, 2012 /PRNewswire/ -- Syngenta today announced that it has received European Union (EU) approval for isopyrazam, the first active ingredient from its strong pipeline of next generation fungicides. Approval represents a major step forward in the control of a wide spectrum of damaging fungal diseases, including best-in-class performance against Yellow Rust.

Isopyrazam's advanced "double-binding" technology ensures strong adhesion to fungus and to leaf wax, providing long-lasting and durable disease protection.

Under the EU's provisional approval system, British and Irish cereal farmers have for the past two growing seasons experienced the benefits of isopyrazam, which is marketed as SEGURIS in wheat and BONTIMAin barley. These growers have consistently achieved better disease control, which has helped deliver higher crop yields: SEGURIS treatments increase yield by up to two tonnes per hectare versus current chemistries.

John Atkin, Chief Operating Officer, said: "Breakthrough chemical innovation is an enduring part of our integrated strategy. Isopyrazam sets the highest standards for disease control and yield response and this approval means growers throughout the EU can now benefit from this important addition to our portfolio."

Syngenta intends to register a range of products containing isopyrazam in major EU markets for use on cereals and others crops such as oilseed rape, vegetables and pome fruits.

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta International AG

Media Office
CH-4002 Basel
Switzerland
Tel: +41 61 323 2323
Fax: +41 61 323 2424

www.syngenta.com

Media contacts:

Paul Barrett
Switzerland +41 61 323 2323

Daniel Braxton
Switzerland +41 61 323 2323

Analyst/Investor contacts:

Jennifer Gough
Switzerland +41 61 323 5059
USA +1 202 737 6521

Lars Oestergaard
Switzerland +41 61 323 6793
USA +1 202 737 6520


'/>"/>
SOURCE Syngenta
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta and Devgen enter insect control research partnership
2. Syngenta to acquire Pasteuria Bioscience
3. Pasteuria Bioscience to be Acquired by Syngenta
4. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
5. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
6. Roka Bioscience Secures $47.5 Million in Series D Financing
7. Generex Secures Commitments for $3.6M Capital Raise
8. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
9. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
10. Bacterin Secures $25 Million Financing with OrbiMed
11. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... NY (PRWEB) , ... July 13, 2017 , ... ... with only two spectrophotometer calibration standards. Blast forward seven years and now ... photometric accuracy, holmium oxide for wavelength accuracy, and resolution testing. ...
(Date:7/13/2017)... ... July 13, 2017 , ... Trinity ... and reusable medical supplies has chosen The Copley Consulting Group to implement and ... seeks to align its internal and backend operations to streamline efficiencies to meet ...
(Date:7/12/2017)... ... July 11, 2017 , ... Business is booming for ... cooking experiences. , Over the past few weeks, Lajollacooks4u has welcomed ... challenges. Founder and Chef Jodi Abel has also lead several Farmers Market ...
(Date:7/12/2017)... ... July 12, 2017 , ... Exact Diagnostics continues to ... In Vitro Diagnostic (IVD) use. Panels available include: Adenovirus, BKV, CMV, ... , The Exact Diagnostics Verification Panels may be used as calibrators to establish reference ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):